Skip to main content
. 2020 Sep 5;190(2):251–264. doi: 10.1093/aje/kwaa176

Table 3.

Factors Associated With Mortality in KIULARCO Participants Under 4 Different Methods of Mortality Estimationa, Ifakara, Tanzania, 2005–2015

Participant Characteristic Method A: Data as Captured in Database Method B: Incorporating Tracing Outcomes Method C: Frangakis and Rubin ( 14 ) Approach Method D: Extension to Frangakis and Rubin ( 14 ) Approach
HR 95% CI HR 95% CI HR 95% CI HR 95% CI
Baseline Covariates
Year of enrollment
 2005–2007 0.94 0.67, 1.32 0.87 0.63, 1.21 0.58 0.37, 0.91 0.62 0.39, 1.00
 2008–2009 1.00 Referent 1.00 Referent 1.00 Referent 1.00 Referent
 2010–2012 0.69 0.51, 0.92 0.98 0.76, 1.26 1.86 1.32, 2.62 1.84 1.30, 2.63
 2013–2015 0.37 0.23, 0.59 0.52 0.34, 0.80 1.18 0.55, 2.50 1.17 0.59, 2.33
Sex
 Male 1.24 1.03, 1.50 1.29 1.08, 1.53 1.32 1.00, 1.73 1.38 1.05, 1.80
 Female 1.00 Referent 1.00 Referent 1.00 Referent 1.00 Referent
Age, years
 15–24 1.05 0.72, 1.53 0.92 0.64, 1.33 0.56 0.31, 0.99 0.56 0.32, 0.99
 25–34 0.85 0.69, 1.05 0.88 0.73, 1.07 0.85 0.62, 1.15 0.86 0.63, 1.18
 35–44 1.00 Referent 1.00 Referent 1.00 Referent 1.00 Referent
 ≥45 1.09 0.89, 1.34 1.12 0.93, 1.35 1.01 0.75, 1.36 0.98 0.73, 1.30
Marital status
 Married/cohabiting 1.00 Referent 1.00 Referent 1.00 Referent 1.00 Referent
 Never married 1.08 0.86, 1.35 1.03 0.84, 1.28 1.04 0.73, 1.47 0.99 0.70, 1.40
 Separated/divorced 0.89 0.68, 1.16 0.92 0.72, 1.16 0.96 0.66, 1.39 1.00 0.69, 1.45
 Widowed/other 0.88 0.66, 1.18 0.86 0.65, 1.13 0.82 0.50, 1.35 0.82 0.50, 1.36
HIV status of partner
 Positive 1.00 Referent 1.00 Referent 1.00 Referent 1.00 Referent
 Negative 1.29 0.82, 2.05 1.21 0.79, 1.85 1.08 0.55, 2.12 1.07 0.55, 2.10
 Unknown 1.22 0.86, 1.74 1.35 0.98, 1.87 1.41 0.86, 2.31 1.45 0.87, 2.40
 Not applicable 1.85 0.99, 3.46 1.95 1.08, 3.52 2.39 0.89, 6.41 2.01 0.78, 5.18
Disclosure of HIV   status
 No 1.00 Referent 1.00 Referent 1.00 Referent 1.00 Referent
 Yes 1.34 1.06, 1.69 1.28 1.03, 1.59 1.03 0.77, 1.38 1.04 0.76, 1.42
Referral to clinic as   hospital inpatient
 No 1.00 Referent 1.00 Referent 1.00 Referent 1.00 Referent
 Yes 1.49 0.99, 2.25 1.45 1.00, 2.11 1.76 1.09, 2.83 1.69 1.02, 2.80
Distance of ward of   residence from   clinic, km
 1 1.00 Referent 1.00 Referent 1.00 Referent 1.00 Referent
 2–49 0.62 0.46, 0.84 0.61 0.46, 0.81 0.64 0.41, 1.00 0.66 0.42, 1.04
 50–79 0.91 0.69, 1.18 0.80 0.62, 1.04 0.51 0.31, 0.86 0.53 0.33, 0.84
 ≥80 0.64 0.48, 0.84 0.65 0.50, 0.85 0.79 0.52, 1.18 0.75 0.49, 1.15
Smoking status
 Never/former smoker 1.00 Referent 1.00 Referent 1.00 Referent 1.00 Referent
 Current smoker 1.22 0.92, 1.61 1.23 0.94, 1.61 1.44 0.99, 2.08 1.39 0.95, 2.02
Pregnant
 No 1.00 Referent 1.00 Referent 1.00 Referent 1.00 Referent
 Yes 0.99 0.49, 2.03 1.26 0.71, 2.19 0.95 0.34, 2.59 1.11 0.41, 2.98
Body mass indexb
 Underweight (<18.5) 1.51 1.16, 1.98 1.56 1.22, 2.00 1.60 1.17, 2.20 1.58 1.15, 2.17
 Normal-weight (18.5–24.9) 1.00 Referent 1.00 Referent 1.00 Referent 1.00 Referent
 Overweight (25.0–29.9) 0.66 0.41, 1.07 0.63 0.40, 1.00 0.66 0.32, 1.35 0.73 0.34, 1.56
 Obese (≥30.0) 0.44 0.14, 1.36 0.32 0.11, 0.94 0.16 0.03, 0.81 0.15 0.03, 0.84
WHO HIV clinical stage
 1 1.00 Referent 1.00 Referent 1.00 Referent 1.00 Referent
 2 1.44 1.08, 1.94 1.45 1.12, 1.89 1.52 1.05, 2.20 1.39 0.95, 2.02
 3 1.90 1.46, 2.49 2.10 1.65, 2.68 2.43 1.69, 3.48 2.32 1.62, 3.32
 4 3.31 2.47, 4.44 3.43 2.60, 4.53 3.16 2.01, 4.99 3.01 1.90, 4.77
CD4 cell count,   cells/mm3
 <100 1.00 Referent 1.00 Referent 1.00 Referent 1.00 Referent
 100–199 0.73 0.54, 0.97 0.73 0.55, 0.96 0.67 0.42, 1.07 0.65 0.41, 1.04
 200–349 0.57 0.41, 0.79 0.59 0.45, 0.78 0.59 0.39, 0.90 0.58 0.39, 0.87
 ≥350 0.32 0.22, 0.46 0.33 0.23, 0.47 0.25 0.15, 0.43 0.24 0.14, 0.43
Tuberculosis
 No 1.00 Referent 1.00 Referent 1.00 Referent 1.00 Referent
 Yes 1.00 0.75, 1.33 0.90 0.69, 1.18 0.75 0.48, 1.19 0.71 0.46, 1.10
Time-Dependent Covariates
Time since ART initiation   during follow-up, months
 Not yet initiated 1.00 Referent 1.00 Referent 1.00 Referent 1.00 Referent
 0.1–5.9 0.23 0.18, 0.29 0.34 0.27, 0.42 0.63 0.47, 0.86 0.6 0.43, 0.84
 6–11.9 0.04 0.02, 0.05 0.06 0.04, 0.08 0.16 0.10, 0.26 0.13 0.08, 0.22
 ≥12 0.03 0.02, 0.05 0.03 0.02, 0.04 0.02 0.01, 0.03 0.01 0.01, 0.02
No. of gaps in care   (periods of LTFU)
 0 1.00 Referent 1.00 Referent 1.00 Referent 1.00 Referent
 1 0.17 0.13, 0.21 0.35 0.29, 0.43 2.30 1.72, 3.06 1.95 1.46, 2.61
 2 0.18 0.11, 0.28 0.24 0.17, 0.36 0.71 0.36, 1.39 0.71 0.37, 1.37
 ≥3 0.17 0.08, 0.35 0.27 0.16, 0.46 1.27 0.58, 2.78 0.98 0.42, 2.28

Abbreviations: ART, antiretroviral therapy; CI, confidence interval; HIV, human immunodeficiency virus; HR, hazard ratio; KIULARCO, Kilombero and Ulanga Antiretroviral Cohort; LTFU, lost to follow-up; WHO, World Health Organization.

a Results were derived from multivariable Cox proportional hazards models adjusting for all variables shown in the table, with multiple imputation for missing baseline covariates (see Methods section of text for details).

b Weight (kg)/height (m)2.